24/7 Market News Snapshot 19 August, 2024 – Alzamend Neuro, Inc. Common Stock (NASDAQ:ALZN)

August 19, 2024

DENVER, Colo., 19 August, 2024 (247marketnews.com) – (NASDAQ:ALZN) are discussed in this article.
Alzamend Neuro, Inc. (NASDAQ:ALZN) has recently experienced a remarkable surge in its stock price, escalating by 254.43% to trade at $7.216 during pre-market hours. This notable increase has attracted significant investor attention, as reflected in a trading volume of 14.19 million shares. The vibrant activity in the stock market indicates a strong market sentiment and burgeoning optimism regarding the company’s innovative neurohealth solutions.

In conjunction with this market excitement, Alzamend has announced a strategic collaboration with a renowned research institution to initiate a groundbreaking Phase II clinical trial for AL001. This therapy is designed to treat patients suffering from post-traumatic stress disorder (PTSD). AL001 employs a novel lithium-delivery system, aiming to leverage the therapeutic benefits of lithium while minimizing the toxicities commonly associated with traditional lithium salts through a patented formulation.

The clinical study will be led by Dr. Ovidiu Andronesi, MD, PhD, an esteemed Associate Professor of Radiology at a prestigious hospital recognized for its rigorous research initiatives. This collaboration is expected to enhance the understanding of lithium distribution in the brain, which is vital for optimizing its safety and efficacy for PTSD patients.

The trial will focus on determining the comparative increases in lithium levels within the brain’s structures, which is essential for formulating optimal dosing strategies. Previous trials conducted by Alzamend have successfully identified maximum tolerated doses for AL001, paving a promising path for individuals seeking relief from PTSD symptoms.

CEO Stephan Jackman expressed enthusiasm over the potential impact of AL001 in improving treatment outcomes for those with PTSD, reflecting Alzamend’s commitment to pioneering innovative therapies. As the study unfolds, further details regarding its timeline and broader implications for the market will be forthcoming, reinforcing Alzamend’s dedication to transforming mental health treatment options.

Related news for (ALZN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.